160970-54-7

• 常用中文名：西洛多辛
• 常用英文名：Silodosin
• CAS号：160970-54-7
• 分子式：C₂₅H₃₂F₃N₃O₄
• 分子量：495.534
• 相关类别： 生物化工 抑制剂 神经信号通路(Neuronal Signaling) Adrenergic Receptor 拮抗剂
• 发布时间：2018-07-25 22:56:35
• 更新时间：2024-01-02 12:25:56
• Silodosin (Rapaflo; KMD-3213)是α1-肾上腺素受体拮抗剂。

名称

• 中文名: 西洛多辛
• 英文名: 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide
• 中文别名: 西罗多辛; 西洛多新; 西洛多辛杂质; 西洛多辛（R）; 2,3-二氢-1-(3-羟丙基)-5-[(2R)-2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙胺基]丙基]-1H-吲哚-7-甲酰胺
• 英文别名: 1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-7-indolinecarboxamide; KAD 3213; 1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide; [3H]-Silodosin; Rapaflo; [14C]-Silodosin; 1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-; UNII-CUZ39LUY82; Silodyx; Urief; Silodosin; KMD-3213

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 601.4±55.0 °C at 760 mmHg
• 熔点: 107 °C
• 分子式: C₂₅H₃₂F₃N₃O₄
• 分子量: 495.534
• 闪点: 317.5±31.5 °C
• 精确质量: 495.234497
• PSA: 97.05000
• LogP: 2.52
• 外观性状: 固体;White to Light yellow powder to crystal
• 蒸汽压: 0.0±1.8 mmHg at 25°C
• 折射率: 1.552
• 储存条件: 存放于惰性气体之中;避免空气
• 水溶解性: 水溶性：不溶；可溶于：乙醇,二甲基甲酰胺,甲醇

生物活性

• 描述: Silodosin (Rapaflo; KMD-3213)是α1-肾上腺素受体拮抗剂。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 肾上腺素能受体
  研究领域 >> 内分泌
• 参考文献:

  [1]. Kobayashi, Shinya; Tomiyama, Yoshitaka; Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia. European Journal of Pharmacology (2009), 613(1-3), 135-140.

  [2]. Tatemichi, Satoshi; Tomiyama, Yoshitaka; Maruyama, Itaru; Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourology and Urodynamics (2006), 25(7), 792-794.

  [3]. Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Expert Opin Pharmacother. 2012 Oc

  [4]. Cui Y, Zong H, Zhang Y.The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis.Int Urol Nephrol. 2012 Aug 24.

  [5]. Goseki T, Ishikawa H, Ogasawara S, Mashimo K, Nemoto N, Taguchi Y, Yago K, Shimizu K.Effects of tamsulosin and silodosin on isolated albino and pigmented rabbit iris dilators: Possible mechanism of intraoperative floppy-iris syndrome.J Cataract Refract Su

安全

• 危害码 (欧洲): Xi

合成路线